TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 34998391
Drug: Chloroquine 150
Normalized name: chloroquine 150 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chloroquine 150 mg (new coated tablet)
Study: 34998391
Drug: Primaquine 15
Normalized name: primaquine 15 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Primaquine 15 mg (new formulation)
Study: 34998391
Drug: Primaquine 5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Primaquine 5 mg (new formulation)
Study: 32162278
Drug: Oral appliance
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral appliance therapy (OAT) with a standardized stepwise titration protocol, starting at 60% of the maximum mandibular protrusion position.
Study: 32205221
Drug: RPC4046 (360
Approvals — FDA: no, EMA: no, PMDA: no
Description: RPC4046 (360 mg/wk)
Study: 32205221
Drug: Placebo followed
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo followed by RPC4046 (360 mg/wk)
Study: 34351020
Drug: FcRn blockers
Normalized name: Ivy Block
Approvals — FDA: no, EMA: no, PMDA: no
Description: FcRn blockers (SYNT001)
Study: 32493407
Drug: Immediate orally
Normalized name: IR-3535
Approvals — FDA: no, EMA: no, PMDA: no
Description: Immediate orally administered amoxicillin (clarithromycin)
Study: 32493407
Drug: Delayed orally
Normalized name: Delayed Release Oral Granules
Approvals — FDA: no, EMA: no, PMDA: no
Description: Delayed orally administered amoxicillin (clarithromycin if penicillin allergic)
Study: 35128820
Drug: 20 g/day
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 g/day SQ-LNS
Study: 34347254
Drug: 150 mg
Normalized name: pectin 150 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 150 mg capecitabine (test formulation)
Study: 34347254
Drug: Branded reference
Normalized name: Eagle Brand Medicated Oil
DrugBank: Eucalyptus oil (DB11114)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Branded reference formulation
Study: 32881921
Drug: Progressive active
Normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Progressive active mobilization with dose and training load control
Study: 32244170
Drug: Scopolamine-augmentation during
Approvals — FDA: no, EMA: no, PMDA: no
Description: Scopolamine-augmentation during exposure therapy
Study: 32244170
Drug: Placebo during
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo during exposure therapy
Study: 35785595
Drug: Investigator-chosen chemotherapy
Normalized name: menthol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Investigator-chosen chemotherapy (ICC)
Study: 35746522
Drug: Half-dose BNT162b2
Normalized name: Half Beta-Prograne
Approvals — FDA: no, EMA: no, PMDA: no
Description: Half-dose BNT162b2 (15 µg)
Study: 35746522
Drug: Standard-dose BNT162b2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard-dose BNT162b2 (30 µg)
Study: 33755149
Drug: WDTE60N (150
Approvals — FDA: no, EMA: no, PMDA: no
Description: WDTE60N (150 mg curcuminoids)
Study: 33755149
Drug: STE95 (500
Approvals — FDA: no, EMA: no, PMDA: no
Description: STE95 (500 mg curcuminoids each)
Study: 35634544
Drug: Madhav Rasayan
Approvals — FDA: no, EMA: no, PMDA: no
Description: Madhav Rasayan Plus tablets (250 mg) twice a day for 15 days, along with standard care (SOC)
Study: 34733674
Drug: Vitamin A
Normalized name: Vitamin A
DrugBank: Vitamin A (DB00162)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vitamin A palmitate (VAP) eye gel
Study: 34733674
Drug: Watson's theory
Approvals — FDA: no, EMA: no, PMDA: no
Description: Watson's theory of care nursing + VAP eye gel
Study: 34733674
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (no VAP eye gel)
Study: 33871949
Drug: ADSCs-assisted AFG
Approvals — FDA: no, EMA: no, PMDA: no
Description: ADSCs-assisted AFG (5 × 10^5 ADSCs/mL fat)
Study: 33243533
Drug: Oral magnesium
Normalized name: Oral Film
DrugBank: Sodium citrate (DB09154)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral magnesium replacement (along with acetaminophen and ondansetron)
Study: 33243533
Drug: Placebo (acetaminophen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (acetaminophen and ondansetron)
Study: 35477611
Drug: REL-1017 25
Normalized name: (2R*,3S)-rel-1,2,3,4-butanetetroltetranitrate
Approvals — FDA: no, EMA: no, PMDA: no
Description: REL-1017 25 mg QD
Study: 35477611
Drug: REL-1017 50
Normalized name: (2R*,3S)-rel-1,2,3,4-butanetetroltetranitrate
Approvals — FDA: no, EMA: no, PMDA: no
Description: REL-1017 50 mg QD
Study: 33400384
Drug: Reminiscence therapy‐based
Approvals — FDA: no, EMA: no, PMDA: no
Description: Reminiscence therapy‐based care program (RTCP)
Study: 32302246
Drug: SPW exercises
Approvals — FDA: no, EMA: no, PMDA: no
Description: SPW exercises with six weekly sessions and home practice
Study: 35192206
Drug: Hand preparation
Normalized name: cranberry preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hand preparation with medicated solution (4% w/v chlorhexidine bigluconate followed by an ABHR)
Study: 35192206
Drug: Application of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Application of a medication solution (benzalkonium chloride 0.1%‐1% and polymeric biguanide hydrochloride 0.01%‐0.1%) followed by an ABHR
Study: 36123240
Drug: Periarticular analgesia
Normalized name: Analgesic Balm GRX
Approvals — FDA: no, EMA: no, PMDA: no
Description: Periarticular analgesia with ropivacaine 300 mg and morphine 5 mg, diluted with saline to 50 ml, plus tranexamic acid (TXA) 2 g injected into the articular cavity after surgery.
Study: 36123240
Drug: Intraarticular injection
Normalized name: dexamethasone
DrugBank: Dexamethasone acetate (DB14649)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Intraarticular injection of 70 mL mixture (ropivacaine 300 mg, morphine 5 mg, and TXA 2 g) after stitching of the joint capsule.
Study: 32072838
Drug: Confidence in
Normalized name: miconazole nitrate Topical Cream [Clearly Confident]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Confidence in using medications correctly
Study: 32072838
Drug: Knowing which
Normalized name: Autologous CD34+ cells transduced with lentiviral vector which encodes for the aryl Sulfatase A complimentary deoxyribonucleic acid sequence
DrugBank: Atidarsagene autotemcel (DB17538)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Knowing which medications to use during a child's serious breathing problem
Study: 35277404
Drug: Pharmacist-participated medication
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pharmacist-participated medication reconciliation
Study: 32029487
Drug: High-dose haemodiafiltration
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose haemodiafiltration (HDF)
Study: 32220632
Drug: SAHELI intervention
Normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: SAHELI intervention (group-based lifestyle change program with weekly classes for 16 weeks and 4 booster classes through month 11)
Study: 35046509
Drug: Physostigmine (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Physostigmine (1 mg)
Study: 35325831
Drug: 0.5 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.5 mg/kg PQQ.Na2
Study: 35325831
Drug: 1 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 mg/kg PQQ.Na2
Study: 35325831
Drug: 2 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 mg/kg PQQ.Na2
Study: 35325831
Drug: 0 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0 mg/kg PQQ.Na2 (Control)
Study: 35917826
Drug: Low-Dose Computed
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-Dose Computed Tomography (LDCT) screening at baseline and after 12 months
Study: 33847066
Drug: Intravitreal triamcinolone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravitreal triamcinolone acetonide (IVTA) 4 mg/0.1 cc at the end of surgery
Study: 33847066
Drug: Topical nepafenac
Normalized name: Nepafenac
DrugBank: Nepafenac (DB06802)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Topical nepafenac sodium 0.1% TID for 1 month post-operation
Study: 33847066
Drug: No adjuvant
Approvals — FDA: no, EMA: no, PMDA: no
Description: No adjuvant therapy (NAT)
Study: 32709920
Drug: Deltamethrin 0.64
Approvals — FDA: no, EMA: no, PMDA: no
Description: Deltamethrin 0.64 mg a.i./L
Study: 32709920
Drug: Deltamethrin 1.40
Approvals — FDA: no, EMA: no, PMDA: no
Description: Deltamethrin 1.40 mg a.i./L
Study: 32709920
Drug: Deltamethrin 15.03
Approvals — FDA: no, EMA: no, PMDA: no
Description: Deltamethrin 15.03 mg a.i./L
Study: 32709920
Drug: Deltamethrin doses
Approvals — FDA: no, EMA: no, PMDA: no
Description: Deltamethrin doses < 3.10 mg a.i./L
Study: 32709920
Drug: Deltamethrin doses
Approvals — FDA: no, EMA: no, PMDA: no
Description: Deltamethrin doses > 3.10 mg a.i./L
Study: 36432420
Drug: Daily calorie
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily calorie restriction (n = 41)
Study: 36432420
Drug: Daily calorie
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily calorie restriction with meal replacement (n = 48)
Study: 33725859
Drug: Supervised heavy‐load
Approvals — FDA: no, EMA: no, PMDA: no
Description: Supervised heavy‐load resistance training (RT) twice a week over the course of chemotherapy (approximately 16‐weeks)
Study: 34351566
Drug: Viscoelastic group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Viscoelastic group (0.15‐0.2 mL of 1.7% sodium hyaluronate injected into the anterior chamber)
Study: 34351566
Drug: Air group
Normalized name: air
DrugBank: Medical air (DB09337)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Air group (anterior chamber filled with air after FCVB implant surgery)
Study: 616121226
Drug: Intravitreal Aflibercept
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravitreal Aflibercept (IAI) single injection (2.0 mg 5 days prior to surgery)
Study: 616121226
Drug: Intravitreal Aflibercept
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravitreal Aflibercept (IAI) double injection (2.0 mg 5 days prior to surgery and additional injection at the time of surgery)
Study: 34010747
Drug: 40 g
Normalized name: PEG-40 GLYCERYL STEARATE
Approvals — FDA: no, EMA: no, PMDA: no
Description: 40 g of EVOO-enriched chocolate
Study: 35818141
Drug: Five-grass SLIT-tablet
Normalized name: Timothy grass pollen extract Sublingual Tablet [Grastek]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Five-grass SLIT-tablet
Study: 35818141
Drug: Ragweed SLIT-tablet
Normalized name: short ragweed pollen extract Sublingual Tablet [Ragwitek]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ragweed SLIT-tablet
Study: 35818141
Drug: House-dust mite
Normalized name: house dust mites
Approvals — FDA: no, EMA: no, PMDA: no
Description: House-dust mite SLIT-tablet
Study: 35818141
Drug: Tree SLIT-tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tree SLIT-tablet
Study: 35818141
Drug: SLIT-tablets
Approvals — FDA: no, EMA: no, PMDA: no
Description: SLIT-tablets
Study: 35358319
Drug: Pharmaceutical care
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pharmaceutical care interventions (PC)
Study: 33393084
Drug: Iloprost 1
Normalized name: ILOPROST 100MCG/ML INJ,SOLN
Approvals — FDA: no, EMA: no, PMDA: no
Description: Iloprost 1 ng/kg/min infusion for 72 hours
Study: 36323988
Drug: Glepaglutide 5
Normalized name: Liraglutide
DrugBank: Liraglutide (DB06655)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Glepaglutide 5 mg subcutaneously once weekly for 6 weeks
Study: 36323988
Drug: Glepaglutide 10
Normalized name: Liraglutide
DrugBank: Liraglutide (DB06655)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Glepaglutide 10 mg subcutaneously once weekly for 6 weeks
Study: 36323988
Drug: Glepaglutide 1
Normalized name: Liraglutide
DrugBank: Liraglutide (DB06655)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Glepaglutide 1 mg intravenous infusion
Study: 33235121
Drug: Chemotherapy combined
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemotherapy combined with Yiqi Huayu Jiedu decoction
Study: 34782701
Drug: Cognitive behavioral
Normalized name: Mahana Parallel Digital Cognitive Behavioral Therapy Mobile Application for Irritable Bowel Syndrome
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive behavioral therapy (CBT) for 12 weeks plus fluoxetine
Study: 34782701
Drug: Cognitive behavioral
Normalized name: Mahana Parallel Digital Cognitive Behavioral Therapy Mobile Application for Irritable Bowel Syndrome
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive behavioral therapy (CBT) for 12 weeks plus placebo
Study: 32139343
Drug: Midazolam-sufentanil based
Approvals — FDA: no, EMA: no, PMDA: no
Description: Midazolam-sufentanil based intravenous anesthesia (IA group)
Study: 36058819
Drug: Laser Acupuncture
Approvals — FDA: no, EMA: no, PMDA: no
Description: Laser Acupuncture Therapy (LAT)
Study: 33993302
Drug: Raltegravir 400
Normalized name: raltegravir 400 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Raltegravir 400 mg + Lamivudine 150 mg twice daily
Study: 32036412
Drug: CC-486 300
Normalized name: CC
DrugBank: Cholecalciferol (DB00169)
Approvals — FDA: no, EMA: no, PMDA: no
Description: CC-486 300 mg daily (Formulation B)
Study: 33522102
Drug: High or
Normalized name: high-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: High or escalating dose methotrexate
Study: 33845473
Drug: Intravenous paracetamol
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous paracetamol (15 mg/kg initially and then 7.5 mg/kg every 6 h)
Study: 33845473
Drug: Intravenous dextrose
Normalized name: Dextrose
DrugBank: Dextrose, unspecified form (DB09341)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous dextrose (control)
Study: 35829783
Drug: Small-quantity lipid-based
Normalized name: guggul lipids
Approvals — FDA: no, EMA: no, PMDA: no
Description: Small-quantity lipid-based nutrient supplements (SQ-LNS) with zinc (0, 5, or 10 mg) or dispersible tablets (5 mg zinc)
Study: 33371027
Drug: More intensive
Normalized name: polyurethane-35 (not more than MPA.S at 40 %)
Approvals — FDA: no, EMA: no, PMDA: no
Description: More intensive treatment for those not meeting PA goals
Study: 33360708
Drug: brief cognitive
Approvals — FDA: no, EMA: no, PMDA: no
Description: brief cognitive behavior group therapy (bCBGT)
Study: 33360708
Drug: psychoeducational-supportive therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: psychoeducational-supportive therapy (PST)
Study: 35678616
Drug: Twice-daily subcutaneous
Normalized name: clindamycin
DrugBank: Clindamycin (DB01190)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Twice-daily subcutaneous dalteparin
Study: 35800262
Drug: Qinxiang Qingjie
Normalized name: Dingxiang
DrugBank: Clove (DB10672)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Qinxiang Qingjie (QXQJ) oral solution
Study: 32294054
Drug: Traditional negative
Normalized name: sodium fluoride
DrugBank: Sodium fluoride (DB09325)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Traditional negative pressure wound therapy (tNPWT)
Study: 34987600
Drug: Mild hypothermia
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mild hypothermia therapy combined with monosialotetrahexosylganglioside (GM1)
Study: 33033025
Drug: 12-week supervised
Normalized name: risedronate
DrugBank: Risedronic acid (DB00884)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 12-week supervised exercise-based intervention comprising a progressive resistance exercise programme two times per week, a protein supplement after exercise, and a home-based walking programme based on daily step counts
Study: 34748774
Drug: 200 mg
Normalized name: RNA 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 200 mg mirikizumab IV every 4 weeks
Study: 34748774
Drug: 600 mg
Normalized name: mesna 600 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 600 mg mirikizumab IV every 4 weeks
Study: 34748774
Drug: 1000 mg
Normalized name: bran 1000 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1000 mg mirikizumab IV every 4 weeks
Study: 34748774
Drug: IV-C (continuation
Approvals — FDA: no, EMA: no, PMDA: no
Description: IV-C (continuation of mirikizumab IV treatment)
Study: 34748774
Drug: 300 mg
Normalized name: rutin 300 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 300 mg mirikizumab SC every 4 weeks
Study: 33234019
Drug: Creatine supplementation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Creatine supplementation (0.1 g·kg‐1·d‐1)
Study: 33234019
Drug: Placebo (0.1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (0.1 g·kg‐1·d‐1)
Study: 33798654
Drug: Voretigene neparvovec
Normalized name: Voretigene Neparvovec
DrugBank: Voretigene neparvovec (DB13932)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Voretigene neparvovec (VN; Luxturna) administered via bilateral subretinal injections in the original intervention group (OI).
Study: 33798654
Drug: Voretigene neparvovec
Normalized name: Voretigene Neparvovec
DrugBank: Voretigene neparvovec (DB13932)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Voretigene neparvovec (VN; Luxturna) administered via bilateral subretinal injections after 1 year in the delayed intervention group (DI).
Study: 33798654
Drug: Voretigene neparvovec
Normalized name: Voretigene Neparvovec
DrugBank: Voretigene neparvovec (DB13932)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Voretigene neparvovec (VN; Luxturna) administered in OI group.
Study: 33798654
Drug: Voretigene neparvovec
Normalized name: Voretigene Neparvovec
DrugBank: Voretigene neparvovec (DB13932)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Voretigene neparvovec (VN; Luxturna) administered in DI group.
Study: 35705263
Drug: Ropivacaine group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ropivacaine group (group R) received additional SFICB using 40 mL of 0.375% ropivacaine.
Study: 35803624
Drug: 500 mg
Normalized name: bran 500 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 500 mg three-times-weekly azithromycin
Study: 36934142
Drug: Tranexamic acid
Normalized name: Tranexamic Acid
DrugBank: Tranexamic acid (DB00302)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Tranexamic acid (1 g intravenously)
Study: 36496259
Drug: ROTEM-guided treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: ROTEM-guided treatment
Study: 32376809
Drug: Oral gargling
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral gargling with an aroma solution
Study: 34473338
Drug: Curcuminoids treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Curcuminoids treatment (exact dosage and duration not specified)
Study: 36484190
Drug: Acupuncture therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acupuncture therapy based on 'gut-brain axis', treated with acupuncture at specific acupoints (Touwei, Shenting, Sishencong, Tianshu, Zhongwan, Zusanli), given once every other day, 3 times a week for 4 weeks, for 3 courses.
Study: 34846698
Drug: Routine treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Routine treatment and WMT
Study: 35747189
Drug: Aprepitant (125
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aprepitant (125 mg orally on day 1, 80 mg on days 2-3) plus palonosetron (0.25 mg intravenously on day 1)
Study: 35747189
Drug: Dexamethasone (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dexamethasone (10 mg intravenously on day 1, 5 mg on days 2-3) plus palonosetron (0.25 mg intravenously on day 1)
Study: 35066948
Drug: Dexamethasone (0.4
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dexamethasone (0.4 mg/kg, maximum 30 mg/day) intravenously for 3 days
Study: 34118562
Drug: NT‐proBNP >
Approvals — FDA: no, EMA: no, PMDA: no
Description: NT‐proBNP > 1500 ?mol/L
Study: 35434156
Drug: Extracorporeal shockwave
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Extracorporeal shockwave therapy (ESWT) along with routine care (CB)
Study: 36215327
Drug: Digital home
Approvals — FDA: no, EMA: no, PMDA: no
Description: Digital home exercise program (12-week duration, 4 exercises daily)
Study: 34743112
Drug: High-frequency, low-dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-frequency, low-dose training
Study: 35618860
Drug: Holmium-166 microspheres
Normalized name: holmium
Approvals — FDA: no, EMA: no, PMDA: no
Description: Holmium-166 microspheres (166Ho-MS) administered after radiofrequency ablation (RFA)
Study: 32546045
Drug: Ibuprofen 10
Normalized name: ibuprofen 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ibuprofen 10 mg/kg q6h and Acetaminophen 15 mg/kg q6h (4-hour dosing interval)
Study: 32546045
Drug: Ibuprofen 10
Normalized name: ibuprofen 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ibuprofen 10 mg/kg q6h and Acetaminophen 15 mg/kg q6h (increased dosing interval by 1 hour)
Study: 36076546
Drug: Naoqingzhiming tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Naoqingzhiming tablet (180-2160 mg)
Study: 33794532
Drug: Hatha yoga
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Hatha yoga (twice a week for 10 weeks)
Study: 35946912
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of hesperidin and diosmin
Study: 35946912
Drug: Oral hypoglycemics
Normalized name: ORAL HYPOGLYCEMIC AGENTS,ORAL
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral hypoglycemics without intervention
Study: 33978907
Drug: enoxaparin 40
Normalized name: ENOXAPARIN 40MG/0.4ML INJ
Approvals — FDA: no, EMA: no, PMDA: no
Description: enoxaparin 40 mg every 12 h (up to 50 mg every 12 h if repeat anti-Xa < 0.1 IU/mL)
Study: 33978907
Drug: enoxaparin 30
Normalized name: ENOXAPARIN 30MG/0.3ML INJ
Approvals — FDA: no, EMA: no, PMDA: no
Description: enoxaparin 30 mg every 8 h
Study: 33978907
Drug: enoxaparin 40
Normalized name: ENOXAPARIN 40MG/0.4ML INJ
Approvals — FDA: no, EMA: no, PMDA: no
Description: enoxaparin 40 mg every 12 h
Study: 33978907
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (anti-Xa ≥ 0.1 IU/mL)
Study: 33978907
Drug: Intervention group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intervention group (anti-Xa < 0.1 IU/mL)
Study: 33095760
Drug: Preventive chemotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Preventive chemotherapy (PC) with albendazole, coverage ranging from 49% to 85%.
Study: 32529493
Drug: Rehabilitative treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rehabilitative treatment (12 sessions, 2/week)
Study: 35354682
Drug: Intra-articular steroid-lidocaine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intra-articular steroid-lidocaine injection (IASLI)
Study: 33326878
Drug: Trauma‐Informed Guilt
Approvals — FDA: no, EMA: no, PMDA: no
Description: Trauma‐Informed Guilt Reduction (TrIGR) therapy
Study: 33326878
Drug: TrIGR therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: TrIGR therapy
Study: 34230526
Drug: Pinaverium 50
Normalized name: pinaverium 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pinaverium 50 mg, three times daily for 4 weeks
Study: 33260253
Drug: Metronidazole (125
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metronidazole (125 mg/mL) at 20 mg/kg PO q12h